Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due ...

The addictive properties of opioids and the lives shattered by their misuse and overprescription are heavily chronicled chapters of the early 21st century. For over 2 decades, scientists in academia ...

A new study adds to evidence which suggests treating breast cancer patients with sodium channel blockers could be a promising future treatment to prevent the spread of cancer during the gap between ...

Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.

Addiction risks from opioid drugs come from their targeting of receptors found primarily in the central nervous system. Other pathways are associated with pain, but many research efforts to hit them ...

Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...

Thomas Kleyman, MD, professor of medicine and chief of the renal-electrolyte division at the University of Pittsburgh Medical Center, is a senior author of the study. Sodium channels found outside the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions ...